Eli Lilly Loses Some Luster

Eli Lilly’s shares are getting hit by the combined pressure from an analyst downgrade and disappointing clinical trial results for a new cancer drug. 
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>